OptiNose, Inc. (OPTN)
- Previous Close
0.9253 - Open
1.2400 - Bid 0.8770 x 100
- Ask 0.9579 x 100
- Day's Range
0.9000 - 1.2500 - 52 Week Range
0.8550 - 2.1000 - Volume
22,014,464 - Avg. Volume
618,543 - Market Cap (intraday)
103.516M - Beta (5Y Monthly) -0.24
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3200 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.75
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
www.optinose.com132
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: OPTN
Performance Overview: OPTN
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OPTN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OPTN
Valuation Measures
Market Cap
104.24M
Enterprise Value
162.30M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.46
Price/Book (mrq)
--
Enterprise Value/Revenue
2.29
Enterprise Value/EBITDA
-10.44
Financial Highlights
Profitability and Income Statement
Profit Margin
-49.99%
Return on Assets (ttm)
-11.29%
Return on Equity (ttm)
--
Revenue (ttm)
70.99M
Net Income Avi to Common (ttm)
-35.48M
Diluted EPS (ttm)
-0.3200
Balance Sheet and Cash Flow
Total Cash (mrq)
73.68M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.69M